How Many Insulet Corporation (NASDAQ:PODD)’s Analysts Are Bullish?

Insulet Corporation (NASDAQ:PODD) Logo
Investors sentiment decreased to 0.95 in Q3 2018. Its down 0.46, from 1.41 in 2018Q2. It fall, as 31 investors sold Insulet Corporation shares while 76 reduced holdings. 44 funds opened positions while 58 raised stakes. 62.28 million shares or 2.48% more from 60.77 million shares in 2018Q2 were reported.
Fiduciary owns 0.02% invested in Insulet Corporation (NASDAQ:PODD) for 6,026 shares. Raymond James Fincl Services Advsrs stated it has 0% of its portfolio in Insulet Corporation (NASDAQ:PODD). Blackrock Inc accumulated 2.76M shares or 0.01% of the stock. Nicholas Investment Partners L P stated it has 42,726 shares or 0.36% of all its holdings. Loomis Sayles Limited Partnership invested in 0.08% or 373,863 shares. State Common Retirement Fund holds 152,668 shares or 0.02% of its portfolio. Teachers Retirement System Of The State Of Kentucky reported 12,493 shares. Principal Financial Inc holds 0% of its portfolio in Insulet Corporation (NASDAQ:PODD) for 13,513 shares. Putnam Lc reported 0.02% of its portfolio in Insulet Corporation (NASDAQ:PODD). Columbus Circle stated it has 443,504 shares or 0.94% of all its holdings. Advisory Rech Incorporated owns 3,543 shares. Guggenheim Limited Com holds 5,977 shares or 0% of its portfolio. Brinker Capital has invested 0.02% of its portfolio in Insulet Corporation (NASDAQ:PODD). Panagora Asset Management, a Massachusetts-based fund reported 7,830 shares. Loring Wolcott And Coolidge Fiduciary Llp Ma accumulated 0% or 1,000 shares.

Since August 14, 2018, it had 0 buys, and 8 sales for $1.34 million activity. $52,133 worth of stock was sold by Abdel-Malek Aiman on Tuesday, August 14. The insider Colleran David sold $491,546. Petrovic Shacey had sold 960 shares worth $100,090.

Insulet Corporation (NASDAQ:PODD) Ratings Coverage

Among 2 analysts covering Insulet (NASDAQ:PODD), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Insulet had 3 analyst reports since October 11, 2018 according to SRatingsIntel. The firm has “Equal-Weight” rating by Morgan Stanley given on Wednesday, January 2. Morgan Stanley maintained the stock with “Equal-Weight” rating in Thursday, October 11 report. Below is a list of Insulet Corporation (NASDAQ:PODD) latest ratings and price target changes.

02/01/2019 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $105 New Target: $90 Maintain
28/11/2018 Broker: UBS Rating: Buy New Target: $105 Initiates Coverage On
11/10/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $96 New Target: $105 Maintain

The stock decreased 0.68% or $0.5 during the last trading session, reaching $72.55. About 164,472 shares traded. Insulet Corporation (NASDAQ:PODD) has risen 20.02% since January 14, 2018 and is uptrending. It has outperformed by 20.02% the S&P500.

Insulet Corporation, a medical device company, develops, makes, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company has market cap of $4.29 billion. The firm offers Omnipod Insulin Management System , which consists of the OmniPod, an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device. It currently has negative earnings. It also customizes the Omnipod System technology platform for the delivery of subcutaneous drugs across various therapeutic areas.

Insulet Corporation (NASDAQ:PODD) Institutional Positions Chart

(adsbygoogle = window.adsbygoogle || []).push({});

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.